I want to know this as well. Presumably it's a small percentage but I also don't think we need a huge market given current market cap and assuming ECYT ultimately does get approval (obviously, an unknown).
2- Curious what imbalances would have specifically caused such different results.
I think this refers to what they cited in the PR pertaining to the initial results wherein the control arm patients received platinum-based therapy at nearly twice the rate of the EC145 arm (#msg-73089346 ).
Market Data 
Markets 
AI
